24.75 USD
▼-3.64-12.82%
盘后 25.25 +2.02%
2026-09-15
市值
$1.51B
市盈率
—
EPS
-9.88
股息率
—
52 周区间
2.53 – 38.33
成交量
1.68M
Beta
1.47
目标价
44.67
52W 低 2.5352W 高 38.33
价格走势
公司简介
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...